Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.
Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S, Salvado O, Bourgeat P, Perez K, Fowler C, Rembach A, Maruff P, Ritchie C, Tanzi R, Masters CL. Villemagne VL, et al. Among authors: ritchie c. Alzheimers Dement (N Y). 2017 Nov 9;3(4):622-635. doi: 10.1016/j.trci.2017.10.001. eCollection 2017 Nov. Alzheimers Dement (N Y). 2017. PMID: 29201996 Free PMC article.
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, Masters CL. Ritchie CW, et al. Arch Neurol. 2003 Dec;60(12):1685-91. doi: 10.1001/archneur.60.12.1685. Arch Neurol. 2003. PMID: 14676042 Clinical Trial.
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI. Adlard PA, et al. Neuron. 2008 Jul 10;59(1):43-55. doi: 10.1016/j.neuron.2008.06.018. Neuron. 2008. PMID: 18614028 Free article.
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW; PBT2-201-EURO study group. Lannfelt L, et al. Lancet Neurol. 2008 Sep;7(9):779-86. doi: 10.1016/S1474-4422(08)70167-4. Epub 2008 Jul 30. Lancet Neurol. 2008. PMID: 18672400 Clinical Trial.
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. Faux NG, et al. J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390. J Alzheimers Dis. 2010. PMID: 20164561 Free article. Clinical Trial.
Is late-onset Alzheimer's disease really a disease of midlife?
Ritchie K, Ritchie CW, Yaffe K, Skoog I, Scarmeas N. Ritchie K, et al. Alzheimers Dement (N Y). 2015 Jul 26;1(2):122-130. doi: 10.1016/j.trci.2015.06.004. eCollection 2015 Sep. Alzheimers Dement (N Y). 2015. PMID: 29854932 Free PMC article. Review.
1,107 results